<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05104125</url>
  </required_header>
  <id_info>
    <org_study_id>ASC40-202</org_study_id>
    <nct_id>NCT05104125</nct_id>
  </id_info>
  <brief_title>Study to Evaluate the Safety and Efficacy of ASC40 in Subjects With Moderate to Severe Acne Vulgaris</brief_title>
  <official_title>A Phase II Randomized, Double-blind, Placebo-controlled, Multi-center, Multi-dose Study to Evaluate Safety and Efficacy of ASC40 Tablets in Subjects With Moderate to Severe Acne Vulgaris.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Ascletis Pharmaceuticals Co., Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Ascletis Pharmaceuticals Co., Ltd.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a phase2, randomized, double-blind, multi-center, multi-dose and placebo parallel&#xD;
      controlled design. The subjects in the study group were given double-blind drugs, and they&#xD;
      were taken (orally) after dinner every day according to the requirements of clinical trial&#xD;
      scheme.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">December 20, 2021</start_date>
  <completion_date type="Anticipated">December 26, 2022</completion_date>
  <primary_completion_date type="Anticipated">September 2, 2022</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Percentage change of total lesion count compared with baseline and week 12.</measure>
    <time_frame>Baseline to week 12</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Ratio of subjects, whose IGA grades was decreased by ≥2 grades compared with baseline at week 12.</measure>
    <time_frame>Baseline to week 12</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>The changes status and changes of average percentage of inflammatory skin lesions count, non-inflammatory skin lesions count and total skin lesions count compared with baseline.</measure>
    <time_frame>Baseline to week 2, 4, 8 and 12</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Ratio of subjects, whose GA grades was 1 or 0, or GA grades was decreased y ≥2 grades compared with baseline and Improvements in classification</measure>
    <time_frame>Baseline to week 2, 4, 8 and 12</time_frame>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Anticipated">180</enrollment>
  <condition>Acne Vulgaris</condition>
  <arm_group>
    <arm_group_label>Experimental group 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>ASC40 25mg for 12 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Experimental group 2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>ASC40 50mg for 12 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Experimental group 3</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>ASC40 75mg for 12 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo group</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo for 12 weeks</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ASC40 25mg</intervention_name>
    <description>25mg of ASC40 orally once daily for 12 weeks.</description>
    <arm_group_label>Experimental group 1</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ASC40 50mg</intervention_name>
    <description>50mg of ASC40 orally once daily for 12 weeks.</description>
    <arm_group_label>Experimental group 2</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ASC40 75mg</intervention_name>
    <description>75mg of ASC40 orally once daily for 12 weeks.</description>
    <arm_group_label>Experimental group 3</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo orally once daily for 12 weeks.</description>
    <arm_group_label>Placebo group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Key Inclusion Criteria:&#xD;
&#xD;
          -  18-40 years old (including 18 and 40 years old);&#xD;
&#xD;
          -  Investigator's Global Assessment of subject at baseline period was at 3-4.&#xD;
&#xD;
          -  Facial skin lesions of subject need counting as follows: 30 ~ 75 inflammatory lesions&#xD;
             (the total number of papules, pustules and nodules is 30 ~ 75, including no more than&#xD;
             2 nodules), 30 ~ 100 non-inflammatory lesions (the total number of open and closed&#xD;
             comedones is 30 ~ 100);&#xD;
&#xD;
        Key Exclusion Criteria:&#xD;
&#xD;
          -  Known to be allergic or hypersensitive to ASC40 tablets;&#xD;
&#xD;
          -  Facial nodules of subject is more than 2 facial nodules&#xD;
&#xD;
          -  The subject with cystic acne&#xD;
&#xD;
          -  Subject with secondary acne such as occupational acne (e.g., chloroacne) and acne&#xD;
             caused by corticosteroids (e.g., chloroacne or acne caused by drugs);&#xD;
&#xD;
          -  Serum AST, ALT≥3ULN and Cr exceeded the upper limit of normal range&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>40 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Leihong Xiang, Doctor</last_name>
    <phone>+86-021-52887783</phone>
    <email>Flora_xiang@vip.163.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Qinyi Chen</last_name>
    <phone>+86-021-52887783</phone>
    <email>qinyi_chen@aliyun.com</email>
  </overall_contact_backup>
  <verification_date>October 2021</verification_date>
  <study_first_submitted>October 26, 2021</study_first_submitted>
  <study_first_submitted_qc>October 26, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">November 2, 2021</study_first_posted>
  <last_update_submitted>October 26, 2021</last_update_submitted>
  <last_update_submitted_qc>October 26, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">November 2, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Acne vulgaris</keyword>
  <keyword>ASC40</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Acne Vulgaris</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

